These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33044511)

  • 1. Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA.
    Zuo Z; Tang J; Cai X; Ke F; Shi Z
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33044511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA.
    Zhang J; Zhang X; Shen S
    Future Oncol; 2020 May; 16(13):849-858. PubMed ID: 32270709
    [No Abstract]   [Full Text] [Related]  

  • 4. Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients.
    Guan G; Wang Y; Sun Q; Wang L; Xie F; Yan J; Huang H; Liu H
    Cancer Biomark; 2020; 28(1):111-119. PubMed ID: 32176625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic landscape of breast cancer and mutation tracking with circulating tumor DNA in Chinese women.
    Wang Y; Lin L; Li L; Wen J; Chi Y; Hao R; Dai X; Chen Y; Huang D; Zhou Y; You J; Ye Z; Chen H; Jin L; Chen D; Yang F; Xia E; Ma X; Guo F; Tong Y; Zheng M; Wang O
    Aging (Albany NY); 2021 Apr; 13(8):11860-11876. PubMed ID: 33893247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
    Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.
    Kodahl AR; Ehmsen S; Pallisgaard N; Jylling AMB; Jensen JD; Laenkholm AV; Knoop AS; Ditzel HJ
    Mol Oncol; 2018 Jun; 12(6):925-935. PubMed ID: 29689598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of circulating DNA from plasma and urine for EGFR mutations in NSCLC patients.
    Zhang H; He B; Cui J; Zhao M; Zhang Z
    Cancer Biomark; 2018; 23(3):427-436. PubMed ID: 30223392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine for Breast Cancer Utilizing Circulating Tumor DNA: It Is in the Blood.
    Miller E; Schwartzberg L
    Curr Treat Options Oncol; 2020 Sep; 21(11):89. PubMed ID: 32875404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.
    Savli H; Sertdemir N; Aydin D; Dursun B; Kurtas O; Reka S; Sunnetci-Akkoyunlu D; Eren-Keskin S; Uygun K; Ozden E; Isik U; Cabuk D; Demir G; Guzdolu E; Gokbayrak M; Aksu MG; Canturk NZ; Cine N
    J Biotechnol; 2019 Jul; 300():87-93. PubMed ID: 31100334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients.
    Lin S; Wang S; Xu B
    J Cancer Res Ther; 2024 Apr; 20(2):563-569. PubMed ID: 38454812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
    Yu H; Han L; Yuan J; Sun Y
    Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
    Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
    Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
    Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.